The Noramco Group, an integrated North American-based API and drug product supply chain product and services provider, is investing $25 million into its Halo Pharma facility in Whippany, New Jersey to establish sterile injectable manufacturing capabilities, including ready-to-use syringe, cartridge, and vial filling.

This expansion aims to address critical capacity shortages in the U.S. injectable supply chain and meet the growing demand from pharmaceutical companies seeking reliable domestic sterile manufacturing partners.

The investment includes the installation of a high-speed Groninger UFVN FlexFill syringe, cartridge, and vial filling line and a SKAN isolator to enhance production efficiency and regulatory compliance. The new capabilities will allow Halo Pharma to manufacture batches ranging from 5,000 to 250,000 units, with an annual production capacity exceeding 50 million units. The initial container systems will include 0.5 mL, 1 mL long, and 1 mL short syringes, along with 2R vials, all in ready-to-fill formats. Container filling can be performed via peristaltic pump or vacuum. Additional syringe, cartridge, and vial options will be introduced based on demand.

“This investment is a significant step in our commitment to build on our position as one of the only fully integrated domestic supply options for our customers,” said Lee Karras, CEO of The Noramco Group. “While this investment enhances our capabilities with contemporary technologies, with the addition of sterile manufacturing we remain committed to our already established and proven focus on manufacturing APIs, oral solid dose, and liquid dosage forms, which continue to be essential in meeting our customers’ needs.”

The Whippany facility, which was historically focused on manufacturing oral solid dose (OSD), semi-solid, and liquid formulations for the past 20 years, will undergo significant renovations to support the new sterile filling line while maintaining its primary production capabilities. The sterile line installation will be carried out over the remainder of 2025, with facility upgrades to meet EU Annex 1 compliance for European market access while maintaining rigorous U.S. quality standards.

The new line strengthens the Noramco Group’s offerings, taking advantage of its already established custom API synthesis business, and supporting the production of new chemical entity (NCE) and generic low bioburden APIs for injectable finished products through its Purisys business unit in Athens, GA. Further investments in packaging automation are planned for 2026.